$25.46+0.11 (+0.43%)
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, Continental Europe, and Australia.
Trupanion, Inc. in the Financial Services sector is trading at $25.46 with a market capitalization of $1.1B. Wall Street consensus targets $39.75 (4 analysts), implying a +56.1% move over the next 12 months. The stock is currently near its 52-week low of $21.16, remaining 20.9% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 79 is overbought against a weak tape. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $384.05M↑ | $376.85M↑ | $366.92M↑ | $353.56M↑ | $341.98M |
| Gross Profit | $61.49M↓ | $65.03M↑ | $60.05M↑ | $54.83M↑ | $51.10M |
| Operating Income | $27.39M↓ | $31.37M↑ | $27.80M↑ | $22.16M↑ | $19.35M |
| Net Income | $4.88M↓ | $5.63M↓ | $5.87M↓ | $9.41M↑ | -$1.48M |
Trupanion, Inc., together with its subsidiaries, provides medical insurance for cats and dogs on subscription basis in the United States, Canada, Continental Europe, and Australia. The company operates in two segments, Subscription Business and Other...
Trupanion (TRUP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
Markets closed a shortened week higher as lower oil prices and a rally in chip stocks outweighed concerns about future Fed policy.
Trupanion is showing stronger earnings, record operating margins, and loyal subscribers, but investors question competition and veterinary inflation.
Trupanion’s latest analyst update comes with no change to the stock’s price target, which keeps the formal outlook exactly where it was before. Even without a fresh target or commentary to unpack, the absence of revisions can still indicate how analysts currently see the risk and reward trade off. As you read on, you will see how to track these kinds of updates so you can follow the evolving narrative around Trupanion more confidently over time. Stay updated as the Fair Value for Trupanion...